Client News

ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board

Client News

LONDON, 12 September 2018: Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announced that industry veteran Arthur Pappas has been appointed … Continue reading “ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board”

By Optimum

Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program

Client News

CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors … Continue reading “Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program”

By Optimum

Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate

Client News

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has raised an additional €4 million of funding from Vesalius Biocapital … Continue reading “Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate”

By Optimum

Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy

Client News

Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced that Dr. Michael Schaeffer has been appointed to the … Continue reading “Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy”

By Optimum

Azeria Therapeutics, the world’s first pioneer factor drug discovery company, announces Series A investment from Sixth Element Capital

Client News

Azeria Therapeutics Limited, a newly formed drug discovery company, today announced that it has successfully raised £4 million in Series A fundraising from the £70 million CRT Pioneer Fund, managed … Continue reading “Azeria Therapeutics, the world’s first pioneer factor drug discovery company, announces Series A investment from Sixth Element Capital”

By Optimum

Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer

Client News

Amsterdam, The Netherlands, August 30, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that Robbert van Heekeren is … Continue reading “Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer”

By Optimum

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

Client News

Novo Nordisk gains full rights to Ziylo’s early-stage glucose binding molecules in a staged acquisition with a potential deal value that could exceed 800 million US dollars The acquisition supports … Continue reading “Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins”

By Optimum

Ziylo acquired by Novo Nordisk in deal that could exceed US$800m

Client News

Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients A new company, Carbometrics, has been set up to develop novel diagnostics and glucose monitoring BRISTOL, … Continue reading “Ziylo acquired by Novo Nordisk in deal that could exceed US$800m”

By Optimum

Arix Bioscience Plc – Artios completes £65m Series B investment round

Client News

Arix interest increased to £15.3 million ($19.7 million1), becoming largest shareholder in Artios. Supporting proven management team in accelerating development of next generation DNA Damage Response (DDR) pipeline Arix Bioscience … Continue reading “Arix Bioscience Plc – Artios completes £65m Series B investment round”

By Optimum

Artios Pharma Announces $84 million (£65 million) Series B Financing

Client News

Financing Round Led by New Investors Andera Partners and LSP Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, today announced the completion … Continue reading “Artios Pharma Announces $84 million (£65 million) Series B Financing”

By Optimum

Arix Bioscience announces first VIPE investment

Client News

Arix Bioscience leads A$24 million (£13.4 million) financing for Pharmaxis Funding to accelerate the development of Pharmaxis’ fibrosis and anti-inflammatory programmes, as the company advances numerous candidates from its Amine … Continue reading “Arix Bioscience announces first VIPE investment”

By Optimum

Oncolytics Biotech: The oncolytic virus renaissance: improving the efficacy of current immunotherapies

Client News

The oncolytic virus renaissance: improving the efficacy of current immunotherapies Oncolytics Biotech Inc. featured in the pharmphorum’s Deep Dive on Oncology Pharma companies are turning to oncolytic viruses to increase … Continue reading “Oncolytics Biotech: The oncolytic virus renaissance: improving the efficacy of current immunotherapies”

By Optimum

Forendo Pharma initiates phase I study for potential new, targeted treatment for endometriosis

Client News

Turku, Finland, July 4 2018: Forendo Pharma, a drug development company focusing on novel oral treatments for endometriosis patients, today announces it has received clinical trial authorisation (CTA) from the … Continue reading “Forendo Pharma initiates phase I study for potential new, targeted treatment for endometriosis”

By Optimum

Evotec and Sanofi sign definitive agreement to combat infectious diseases

Client News

Hamburg, Germany, 18 June 2018: Evotec AG today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec … Continue reading “Evotec and Sanofi sign definitive agreement to combat infectious diseases”

By Optimum

Apitope Announces Positive Results with Novel Treatment for Graves’ Disease

Client News

HASSELT, Belgium and CHEPSTOW, Wales, April 16, 2018 /PRNewswire/ — Phase I data show early efficacy in the majority of patients and a very favourable safety profile Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific … Continue reading “Apitope Announces Positive Results with Novel Treatment for Graves’ Disease”

By Optimum

Macrophage Pharma appoints Dr Michael Moore as Chairman

Client News

11 April 2018, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other … Continue reading “Macrophage Pharma appoints Dr Michael Moore as Chairman”

By Optimum

Bionical Group Ltd today announces the launch of Bionical-Clinical early access programs (EAP)

Client News

Bionical Clinical EAP is the first and only global specialist Early Access Program partner that harnesses the full power of an established and successful Clinical Research Organization whilst applying a deep … Continue reading “Bionical Group Ltd today announces the launch of Bionical-Clinical early access programs (EAP)”

By Optimum

STORM Therapeutics wins Life Science Innovation Award

Client News

STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced that it has won the Life Science Innovation Award at the Business … Continue reading “STORM Therapeutics wins Life Science Innovation Award”

By Optimum

Apitope Announces Publication of Data in International Peer-Reviewed Journal Neurology on Novel Multiple Sclerosis Therapy

Client News

HASSELT, Belgium, and CHEPSTOW, UK, 19 March 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced publication of data on it multiple … Continue reading “Apitope Announces Publication of Data in International Peer-Reviewed Journal Neurology on Novel Multiple Sclerosis Therapy”

By Optimum